Reena Bansal, MD
Critical Care Medicine · Scottsdale, AZNPI 1366857187
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (56.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 70.7% of it on its own, with 33 other manufacturers making up the rest. 2025 is the largest year on record at $7,768, more than ten times the $13 reported in 2020. Among critical care medicine clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 141 payments — averaging $71.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- GSK$381
- AstraZeneca$265
- Astellas Pharma US Inc$243
- Regeneron Healthcare Solutions, Inc.$207
- Actelion Pharmaceuticals US, Inc.$200
- plus $2K from 28 others
What the payments were for
- Travel & lodging$1,17512%
- Food & beverage$3,23932%
- Education$5,70056%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 11 | $7,153 |
| GSK | 18 | $381 |
| AstraZeneca | 14 | $265 |
| Astellas Pharma US Inc | 4 | $243 |
| Regeneron Healthcare Solutions, Inc. | 7 | $207 |
| Actelion Pharmaceuticals US, Inc. | 7 | $200 |
| Grifols USA, LLC | 8 | $195 |
| Boehringer Ingelheim | 9 | $170 |
| Amgen | 9 | $148 |
| Caris MPI, Inc. | 1 | $140 |
| United Therapeutics Corporation | 5 | $116 |
| Merck | 6 | $105 |
| Sanofi | 4 | $96 |
| Jazz Pharmaceuticals Inc. | 4 | $95 |
| Electromed, Inc. | 9 | $83 |
| Mylan Specialty L.p. | 4 | $83 |
| Viiv Healthcare Company | 2 | $48 |
| CSL Behring | 2 | $43 |
| Lilly USA, LLC | 2 | $35 |
| Verona Pharma, Inc. | 1 | $34 |
| UCB, Inc. | 1 | $31 |
| Pulmonx Corporation | 1 | $26 |
| Viatris Specialty LLC | 1 | $26 |
| Pfizer | 1 | $25 |
| Advanced Respiratory, Inc | 1 | $23 |
| Abiomed | 1 | $20 |
| Eisai Inc. | 1 | $19 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $17 |
| Tandem Diabetes Care, Inc. | 1 | $16 |
| CMP Pharma, Inc. | 1 | $16 |
| Dova Pharmaceuticals | 1 | $16 |
| Philips North America LLC | 1 | $15 |
| Exelixis Inc. | 1 | $14 |
| 3b Medical, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$7,010
- MI CANCER SEEK$140
How this compares
$10,113 in reported general payments places this provider in the 95th percentile of 175 critical care medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 227 | $191,388 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 126 | $82,816 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 86 | $49,798 |
| Breo ElliptaFluticasone/Vilanterol | 54 | $24,305 |
| Spiriva RespimatTiotropium Bromide | 29 | $18,042 |
| Advair HfaFluticasone Propion/Salmeterol | 35 | $14,907 |
| Spiriva HandihalerTiotropium Bromide | 21 | $12,973 |
| SymbicortBudesonide/Formoterol Fumarate | 47 | $11,305 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 23 | $10,563 |
| Itraconazole | 25 | $4,459 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $3,855 |
| Fluconazole | 69 | $3,537 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $2,909 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 104 | $2,892 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $1,312 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $381 | $269,346378 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $265 | $94,121173 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $170 | $28,60552 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 175 critical care medicine providers in Arizona.
Other critical care medicine in Scottsdale
- Akshay MuralidharScottsdale$44K
- Rodrigo Cartin-CebaScottsdale$18K
- Kenneth SakataScottsdale$4K
- Heemesh SethScottsdale$4K
- Sandra TillScottsdale$3K
- Aditya GuptaScottsdale$3K
- Pritesh PatelScottsdale$3K
- Benjamin CantrillScottsdale$2K
- Randy WeismanScottsdale$2K
- Harseerat RataulScottsdale$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.